Risk management materials for Valdoxan (agomelatine) – liver function monitoring and drug interactions -

Risk management materials for Valdoxan (agomelatine) – liver function monitoring and drug interactions
Information type: Safety alerts
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Liver disorders | Mental health and illness
Summary
New guidance for healthcare professionals has been provided for monitoring liver function in patients before and during treatment with Valdoxan. Concomitant use of potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) is also contraindicated with Valdoxan.
UKMi comment
Accompanying documents to the prescriber’s guidance for Valdoxan includes a liver function monitoring pathway and a patient alert card.
Related links: Monitoring pathway Patient alert card